Why should we care about upper airway inflammation in obstructive sleep apnoea?

Malcolm Kohler\textsuperscript{1,2}

\textbf{Affiliations}: \textsuperscript{1}Dept of Pulmonology, University Hospital of Zurich, Zurich, Switzerland. \textsuperscript{2}Interdisciplinary Center for Sleep Research, University of Zurich, Zurich, Switzerland.

\textbf{Correspondence}: Malcolm Kohler, Dept of Pulmonology, University Hospital of Zurich, Raemistrasse 100, 8091 Zurich, Switzerland. E-mail: Malcolm.Kohler@usz.ch

\textbf{@ERSpublications}

Treatment of upper airway inflammation may be a novel therapeutic approach in obstructive sleep apnoea\textsuperscript{http://ow.ly/jeal302QSqc}

There is a number of reasons why the article by VINCENTE \textit{et al.} \cite{1} published in this issue of the \textit{European Respiratory Journal} deserves a second thought. It is one of the very few studies that addresses the hypothesis that there may be some "spill-over" effect of inflammation from the upper airway into the blood circulation in patients with obstructive sleep apnoea (OSA) \cite{1–3}. According to this hypothesis, which has also been proposed as a mechanism to explain raised blood inflammatory marker levels in other diseases, such as chronic obstructive pulmonary disease \cite{4}, local inflammation results in an increased production of inflammatory cytokines and proteins that reach the plasma. These enhance systemic inflammation and thereby contribute to pathophysiological effects of chronic inflammation, such as disturbed lipid and glucose metabolism, and ultimately, development of atherosclerosis. However, recently the spill-over hypothesis has been discussed controversially \cite{4}.

VINCENTE \textit{et al.} \cite{1} present an elegant approach to evaluate a possible association between local upper airway inflammation and systemic disease; the authors collected pharyngeal lavage (PHAL) and plasma at the same time, and determined levels of several pro-inflammatory markers, such as interleukin (IL)-6, IL-8, tumour necrosis factor-\(\alpha\) and C-reactive protein, and leukocytes in OSA patients (n=89), snorers (n=28) and healthy control subjects (n=26). Participants were re-assessed 12 months after their initial visit. Interestingly, VINCENTE \textit{et al.} \cite{1} found higher IL-6, IL-8 and CD4\(^+\) T-cells in the PHAL of severe OSA patients (apnoea–hypopnoea index (AHI) \(\geq 30\) per h) compared to the snoring and healthy control groups. In addition, there was an association of PHAL levels of IL-6, IL-8 and CD4\(^+\) T-cells with AHI, and treatment with continuous positive airway pressure (CPAP) for 12 months resulted in decreased PHAL levels of these inflammatory markers. In contrast, none of the inflammatory cytokines or any subtype of lymphocyte levels in plasma differed between patients with severe OSA and control groups. There was also no association between plasma and PHAL inflammatory markers, and last but not least, CPAP treatment had no effect on plasma inflammatory markers.

What do these findings tell us? The authors correctly state in the discussion of the manuscript that to definitely reject the spill-over hypothesis, one would possibly need a specific inflammatory marker produced in the upper airway that could then be measured in blood. The inflammatory cytokines used in the study by VINCENTE \textit{et al.} \cite{1} are those that are proposed in the literature to stem from OSA-induced intermittent hypoxia and oxidative stress, and have been associated with detrimental effects on endothelial structure and function \cite{5}. As there was no association between PHAL and plasma levels of these inflammatory markers, and CPAP only had an effect on local inflammation, one must conclude that upper airway inflammation in OSA patients is not contributing to the possibly clinically more relevant systemic inflammation.

Received: June 23 2016 | Accepted: July 09 2016

Support statement: This work was supported by Swiss National Science Foundation grant 32003B_162534/1 and the University of Zurich Clinical Research Priority Programme Sleep and Health. Funding information for this article has been deposited with the Open Funder Registry.

Conflict of interest: Disclosures can be found alongside this article at erj.ersjournals.com

Copyright ©ERS 2016
This study also adds some additional evidence to the debate of whether or not OSA is associated with systemic inflammation [6, 7]. Although it has all the limitations of a case–control study and was not primarily designed to assess the effects of CPAP therapy on systemic inflammatory markers, the authors did not find any association between OSA severity and plasma inflammatory markers, and also found no effect of CPAP on these markers. The study thus corroborates the findings of multiple randomised controlled trials showing no effect of CPAP on systemic inflammatory markers [8–11].

Perhaps the most important point is that Vincente et al. [1] draw our attention to a potential new treatment approach for OSA. There is some preliminary work suggesting that local and systemic inflammation may impair respiratory muscle contractility and muscle control function [12–14]; thus, local upper airway mucosal inflammation and swelling effectively, this could provide a novel treatment option to be explored in OSA.

References


DOI: 10.1183/13993003.01248-2016